DORMATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DORMATE (DORMATE).
Gamma-aminobutyric acid (GABA) type A receptor positive allosteric modulator; increases chloride ion influx, enhancing inhibitory neurotransmission.
| Metabolism | Hepatic via CYP3A4; major metabolite is zolpidem phenyl-4-carboxylic acid (inactive). |
| Excretion | Primarily renal excretion (60-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 15-25%. |
| Half-life | Terminal elimination half-life 8-12 hours in healthy adults; prolonged in renal impairment (up to 30 hours) and elderly. |
| Protein binding | 95-98% bound to albumin. |
| Volume of Distribution | 5-10 L/kg; large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: 80-90% due to extensive absorption and moderate first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | 4-8 hours depending on dose and route; shorter with IV due to redistribution. |
10 mg orally once daily at bedtime, not to exceed 10 mg/day.
| Dosage form | TABLET |
| Renal impairment | CrCl ≥30 mL/min: no adjustment. CrCl <30 mL/min: not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended due to increased risk of encephalopathy. |
| Pediatric use | Not approved for use in pediatric patients (<18 years). |
| Geriatric use | 5 mg orally once daily at bedtime; increase to 10 mg if needed and tolerated. Caution due to increased sensitivity and risk of falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DORMATE (DORMATE).
| Breastfeeding | Meprobamate is excreted into human breast milk with a milk-to-plasma ratio of approximately 2-4 (range 1.7-4.5). Milk concentrations can reach 50-100% of maternal serum levels. The American Academy of Pediatrics considers Meprobamate to be a drug whose effect on nursing infants is unknown but may be of concern. Sedation, poor feeding, and potential withdrawal in the infant have been reported. If used during breastfeeding, monitor infant for excessive drowsiness, and consider alternative therapy. Avoid breastfeeding if possible during chronic therapy. |
| Teratogenic Risk | Dormate (Meprobamate) is classified as FDA Pregnancy Category D. There is evidence of human fetal risk, but potential benefits may warrant use in pregnant women despite risks. First trimester: Increased risk of major malformations, particularly cardiovascular defects, cleft palate, and neural tube defects, as observed in epidemiological studies. Second and third trimesters: Exposure may lead to withdrawal symptoms (e.g., irritability, tremors, hypertonia) in the neonate, and prolonged exposure may cause low birth weight. Neonatal sedation and respiratory depression may occur if used near delivery. |
■ FDA Black Box Warning
Complex sleep behaviors including sleep-driving, making phone calls, preparing and eating food, and other activities while not fully awake have been reported with hypnotic agents like DORMATE. Discontinue immediately if such behaviors occur.
| Serious Effects |
Hypersensitivity to zolpidem, severe hepatic impairment, history of complex sleep behaviors, concurrent use with alcohol or other CNS depressants, pregnancy (category C), nursing mothers.
| Precautions | Risk of CNS depression, impaired daytime function, anaphylaxis, angioedema, depression exacerbation, respiratory depression (especially in COPD/sleep apnea), withdrawal symptoms upon abrupt discontinuation. |
Loading safety data…
| Fetal Monitoring | Maternal: Regular monitoring of mental status, sedation level, liver function tests, and complete blood counts (due to risk of agranulocytosis). Fetal/Neonatal: Fetal ultrasound for malformations if exposed in first trimester; after second/third trimester exposure, monitor neonate for signs of withdrawal (jitteriness, hypertonia, poor feeding, respiratory depression) for at least 48 hours. Long-term neurodevelopmental follow-up is recommended. |
| Fertility Effects | Data on human fertility effects are limited. Animal studies have shown no direct impairment of fertility at therapeutic doses, but chronic use may affect hormonal regulation and menstrual cyclicity due to CNS depression and possible disruption of hypothalamic-pituitary-ovarian axis. In males, there is a theoretical risk of reduced libido or erectile dysfunction secondary to sedation. Discontinuation of meprobamate may restore fertility. For reliable contraception, discuss alternative therapies to avoid potential fetal risks. |